Tissue Repair & Regeneration

MGF (Mechano Growth Factor)

MGF (Mechano Growth Factor) is a naturally occurring splice variant of IGF-1 that activates muscle stem cells in preclinical models, though it lacks human clinical trials and remains unapproved.

Editorial team ·Updated ·10 Sources ·evidence-rated ·independent & ad-free

Common use common practice, unverified

How this peptide is typically used - described, not recommended.

How much
100-300 µg per dose
How often
2-3 times a week
Administration
Injection

In bodybuilding forums, people report using MGF at 100 to 300 micrograms per injection, two to three times a week, right after training. One described four-week build-up phase starts at 100 to 200 micrograms and can optionally go up to 300 micrograms. These numbers are not clinically verified: there are no human studies and no approval for MGF. They are just a reference from gray-area use.

Still experimental evidence (level < 3) - we deliberately do not provide an injection calculation here.

As of

In brief: MGF (Mechano Growth Factor) is an endogenous messenger substance produced in muscle tissue when it is stressed or injured. Research investigates whether MGF supports muscle regeneration. Important upfront: MGF is not an approved medicine, there are no controlled human trials, and its use is strictly prohibited in sports.

What is MGF?

MGF (Mechano Growth Factor), also known as IGF-1Ec, is a naturally occurring splice variant of insulin-like growth factor 1 (IGF-1) that is locally expressed in skeletal muscle and tissue following mechanical load, stretching, or injury, acting as a rapid signal for muscle repair and stem cell activation.

Discovered in the early 2000s, it arises through alternative splicing of the IGF-1 gene. Unlike systemic IGF-1Ea, which circulates throughout the body via the liver, MGF acts locally. A critical issue in the scientific literature is the problematic nomenclature: the term "MGF" is often used ambiguously. Researchers frequently fail to distinguish whether they are referencing the full-length MGF molecule or solely the 24-amino-acid E-peptide, making direct comparisons between studies highly difficult.

Agent Class / Mechanism Effect Size / Evidence Approval Status
Native MGF (IGF-1Ec) Local IGF-1 splice variant (E-peptide) Strong preclinical data, 0 human trials Unapproved / WADA Prohibited
PEG-MGF PEGylated full-length MGF peptide (longer half-life) Widely used in research/anecdotal, 0 human trials Unapproved / WADA Prohibited
Systemic IGF-1 Full-length systemic growth factor Clinical data exists, systemic anabolic effects Approved for specific rare diseases

How does MGF work?

MGF operates through a dual mechanism where the full-length molecule binds to the IGF-1 receptor to promote protein synthesis, while its specific C-terminal E-peptide acts autonomously to rapidly activate dormant muscle satellite stem cells, increasing their multiplication and fusion potential without causing premature maturation.

When muscle fibers are damaged, the localized MGF pulse triggers the proliferation of these progenitor cells. In laboratory settings (in vitro), this specific mechanism has been shown to delay the replicative senescence (the natural end of a cell's ability to divide) of muscle cells by an estimated 14 %.

Because native MGF is broken down extremely quickly in the body, researchers and unregulated markets frequently utilize PEG-MGF (PEGylated Mechano Growth Factor). Attaching a polyethylene glycol molecule to the peptide significantly increases its stability, plasma half-life, and overall duration of action in the body.

How effective is MGF?

The effectiveness of MGF is currently supported almost exclusively by preclinical models-such as in vitro cell cultures and animal experiments-which demonstrate muscle regeneration, reduced oxidative stress, and tissue protection, whereas robust clinical trials proving these benefits in humans are completely absent.

Animal models indicate that MGF can reduce inflammatory hormones and oxidative stress following injury. Beyond skeletal muscle, research explores its role in cartilage repair, wound healing, and neuroprotection following brain injuries. However, the scientific consensus is not absolute.

A notable contradiction exists in the broader literature: while several early studies confirmed that the E-peptide successfully activates muscle stem cells, a subsequent study by Fornaro et al. found that the MGF peptide had no observable effect on muscle myoblasts or primary muscle stem cells. This discrepancy, possibly linked to nomenclature issues, means its definitive biological efficacy remains debated.

Dosage: what the studies show - and the progression

There is no clinically validated or approved human dosage for MGF, meaning any dosing data originates strictly from experimental literature and anecdotal bodybuilding protocols, where users typically utilize the more stable PEG-MGF variant rather than the rapidly degraded native peptide to sustain biological activity.

Phase / Context Agent Anecdotal Dose Goal / Note
Post-Training (Anecdotal) Native MGF 100 - 300 mcg Injected locally; rapidly degraded
Weekly Cycle (Anecdotal) PEG-MGF 200 - 400 mcg Longer half-life, systemic reach
Clinical Validation N/A None No established safe human dose

Handling & Storage

Because exogenous MGF is typically synthesized as a lyophilized (freeze-dried) research chemical, proper handling requires careful reconstitution with sterile bacteriostatic water and strict storage in a refrigerated environment to prevent the rapid degradation and loss of biological activity inherent to unmodified peptide chains.

Once reconstituted, peptide stability is highly sensitive to temperature fluctuations and light exposure. Furthermore, because products sold online are marketed strictly as "research chemicals," they bypass pharmaceutical manufacturing standards, carrying inherent risks of contamination or inaccurate dosing that require rigorous harm-reduction awareness.

Side effects and common mistakes

The side effect profile of exogenous MGF is poorly understood due to a lack of human trials, but theoretical and anecdotal evidence points to significant risks including potentially cancer-promoting (carcinogenic) effects, alongside common acute reactions such as injection site irritation, dizziness, and nausea.

Due to its potent growth-factor properties, exogenous MGF is strictly contraindicated for individuals with pre-existing conditions such as cancer, diabetes, or severe kidney disease. Theoretical interactions with blood thinners and diabetes medications are also noted within harm-reduction circles.

  • Confusing native MGF with PEG-MGF: Native MGF has a half-life of mere minutes; expecting prolonged effects without PEGylation is a common misunderstanding.
  • Ignoring cancer risks: As a potent tissue-growth promoter, utilizing MGF with undiagnosed tumors or active cancers poses severe theoretical risks.
  • Assuming human efficacy from mouse data: Many users extrapolate muscle regeneration results directly from rodent studies, ignoring the complete lack of human pharmacokinetic data.

MGF is globally unapproved as a medical treatment for any condition in regions including the EU, Germany, and the USA, and because of its highly anabolic and muscle-repairing properties, it is explicitly prohibited by the World Anti-Doping Agency (WADA) for all competitive athletes.

Commercially, MGF and PEG-MGF are sold exclusively as unregulated "research chemicals" or "investigational compounds," meaning they bypass the strict safety and efficacy requirements of agencies like the FDA or EMA. While possession for research purposes may not be strictly illegal depending on the jurisdiction, utilizing these unapproved products for human enhancement carries substantial health risks and violates sporting regulations globally.

Evidence at a glance

Research status
The research status for Mechano Growth Factor (MGF) is entirely preclinical, with biological effects supported only by cell culture and animal models across muscle, bone, neural, and cardiac tissues [1][2][4][5]. No human interventional clinical trials for MGF as a therapeutic agent exist [15][16][17]. The preclinical evidence quality is weakened by contradictory in vitro results and an editorial questioning the peptide's proposed functions [6][8][10]. MGF is not approved for any medical use [21][22].
Human evidence
Human evidence is limited to observational findings regarding endogenous expression. MGF/IGF-1Ec is upregulated during exercise and in injured/damaged skeletal muscles in humans, with a 2017 study providing evidence for its differential regulation after exercise-induced muscle damage [5]. No interventional clinical trials of MGF as a therapeutic agent were identified; ClinicalTrials.gov records found concern recombinant human IGF-1 (rhIGF-1), not MGF [15][16]. One observational, cross-sectional study (NCT07151807) investigates the relationship between serum IGF-1Ec levels and tumor burden, but this is a biomarker study, not a therapeutic intervention [17].
Dosages in studies & practice
No human dosing data for MGF exist in the provided sources [22]. No clinical trial protocols, dosing studies, or anecdotal dosing reports were found [15][16]. Animal or cell-study concentrations are not presented in a way that would support a reliable dosing summary, and any dosing information circulating in non-scientific contexts is not supported by the provided evidence base.
Risks & side effects
The FDA has identified no human exposure data for PEGylated MGF (PEG-MGF) [22]. Compounded drugs containing PEG-MGF may pose a significant risk for immunogenicity for certain routes of administration and may have complexities regarding peptide-related impurities and API characterization [22]. Marketing MGF as supplements or performance enhancers violates federal law [21]. The provided sources do not contain sufficient evidence to determine whether MGF-related products affect tumor risk, glucose regulation, or other clinically important outcomes [17].
Research gaps
Major research gaps include the complete absence of human therapeutic trials, as the evidence base is entirely preclinical [1][2][3][4][5][6][8][11][14]. Contradictory in vitro results regarding MGF's effects on muscle cells remain unresolved [6][8], and an editorial explicitly questions the validity of earlier positive findings [10]. No human safety data exist for PEG-MGF [22]. Mechanism uncertainty persists, as structure-function relationships are not fully clarified [8], and historical nomenclature confusion across species complicates literature interpretation [2].

Editorial, sourced from primary literature - not medical advice.

Related peptides

Still experimental evidence (level < 3) - we deliberately do not provide an injection calculation here.

← Back to peptides

The Peptide Signal - monthly, ad-free Learn more